Managers / Q1 2025 · view latest →
Foresite Capital Management VI LLC
CIK 0002013341 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management Vi LLC reported $183M in U.S.-listed holdings across 14 positions for Q1 2025.
The portfolio is heavily concentrated: CGON alone accounts for 29.8% of reported value.
The book was largely unchanged from Q4 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 76.2% · $139M
- ADR · 13.9% · $25M
- Other · 9.9% · $18M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | HELD | +0 | 2.22M | −$9M | $54M |
| ALMSAlumis Inc | HELD | +0 | 4.20M | −$7M | $26M |
| AKROAkero Therapeutics Inc | HELD | +0 | 365.0K | +$5M | $15M |
| Rapt Therapeutics Inc | HELD | +0 | 12.50M | −$5M | $15M |
| BCAXBicara Therapeutics Inc | HELD | +0 | 950.0K | −$4M | $12M |
| GPCRStructure Therapeutics Inc | HELD | +0 | 420.0K | −$4M | $7M |
| CRVSCorvus Pharmaceuticals Inc | HELD | +0 | 1.58M | −$3M | $5M |
| 260Centessa Pharmaceuticals Inc | HELD | +0 | 1.25M | −$3M | $18M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc.history → | COM | 29.80% | $54M | 2.22M |
| 2 | ALMSAlumis Inchistory → | COM | 14.14% | $26M | 4.20M |
| 3 | 260Centessa Pharmaceuticals Inchistory → | SPONSORED ADS | 9.87% | $18M | 1.25M |
| 4 | Rapt Therapeutics Inc | COM | 8.35% | $15M | 12.50M |
| 5 | AKROAkero Therapeutics Inchistory → | COM | 8.09% | $15M | 365.0K |
| 6 | EWTXEdgewise Therapeutics Inchistory → | COM | 7.05% | $13M | 585.0K |
| 7 | BCAXBicara Therapeutics Inchistory → | COM | 6.78% | $12M | 950.0K |
| 8 | GPCRStructure Therapeutics Inchistory → | SPONSORED ADS | 3.98% | $7M | 420.0K |
| 9 | ALLOAllogene Therapeutics Inchistory → | COM | 2.76% | $5M | 3.45M |
| 10 | CRVSCorvus Pharmaceuticals Inchistory → | COM | 2.75% | $5M | 1.58M |
| 11 | CGEMCullinan Therapeutics Inchistory → | COM | 2.63% | $5M | 634.6K |
| 12 | KYMRKymera Therapeutics Inchistory → | COM | 2.19% | $4M | 146.3K |
| 13 | Casi Pharmaceuticals Inc | ORD SHS | 1.57% | $3M | 1.33M |
| 14 | VRDNViridian Therapeutics, Inc | COM | 0.01% | $26,610 | 2.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $460M | 17 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $331M | 12 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $259M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $178M | 20 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $183M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $224M | 14 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.